Olivia Esposito • July 28, 2023
HCMA’s August 2023 Featured Discussion Group Leader:  Linda Montgomery

Linda hosts our “Newly Diagnosed” education groups. These free online education sessions are ideal for those newly diagnosed (within the past two years) or those new to the HCMA. Linda offers several dates ×s each month to make it convenient for all to attend.

About Linda:  I am one of seven children, which has taught me how to get along with different personalities, stand up for those who need it, and never forget where I came from.  I’ve had an amazing career in Global Pharmaceuticals over the past couple of decades.  Getting closer to the patients was always my goal, so I changed careers and entered Patient Advocacy as an employee of the HCMA.  As an HCMA employee and a Discussion Group Leader of the Newly Diagnosed, I’ve had the privilege of conducting many of your Intake Calls. I hope I’ve made you feel warmly welcomed into the HCMA community.

While I do not have HCM, I am passionate about helping people with rare diseases and transplantation.  I work as a volunteer for an Organ Donation group.

I live in NJ, and in my time away from the office, I enjoy visiting my son in Dallas, spending time with my English Bulldogs, and being outdoors.

To view our event calendar for meeting dates and times, please click the following link:  Patient Discussion Groups – Hypertrophic Cardiomyopathy Association (4hcm.org)

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts